Related Experiment Video
Updated: Jun 1, 2026

A Human Peripheral Blood Mononuclear Cell (PBMC) Engrafted Humanized Xenograft Model for Translational Immuno-oncology (I-O) Research
Published on: August 15, 2019
Immune modulatory agents in hematopoietic malignancies
Irina Idler1, Nupur Bhattacharya, Hartmut Döhner
1Innere Medizin III, Uniklinik Ulm, Albert-Einstein-Allee 23, 89081 Ulm, Germany.
Immune modulatory drugs have been successfully used to treat patients with multiple myeloma (MM), myelodysplastic syndromes displaying loss of 5q (del5q MDS) and chronic lymphocytic leukemia (CLL). Immune modulatory drugs are used in first-line therapy in combination with functionally complementary compounds, but have also shown efficacy in refractory disease. However, their exact mode of action remains unclear. Here we describe the clinical impact of these compounds on MM, del5q MDS and CLL, discuss their mode of action with respect to intracellular targets, focus on the phenotypic changes that immune modulatory compounds induce in the tumor microenvironment and how they modulate the immune response.
Immune modulatory drugs have been successfully used to treat patients with multiple myeloma (MM), myelodysplastic syndromes displaying loss of 5q (del5q MDS) and chronic lymphocytic leukemia (CLL). Immune modulatory drugs are used in first-line therapy in combination with functionally complementary compounds, but have also shown efficacy in refractory disease. However, their exact mode of action remains unclear. Here we describe the clinical impact of these compounds on MM, del5q MDS and CLL, discuss their mode of action with respect to intracellular targets, focus on the phenotypic changes that immune modulatory compounds induce in the tumor microenvironment and how they modulate the immune response.
Related Concept Videos
Regulation of Hematopoietic Stem Cells
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Role of Hematopoietic Growth Factors
Thrombopoietin (TPO), mainly released by the liver,...
Differentiation of Common Myeloid Progenitor Cells
Mesenchymal Stem Cells
Tumor Immunotherapy